Obesity evidence dossier
Foundayo (orforglipron)
Likely most important for patients who strongly prefer a pill, even if injectable medicines show higher average weight loss.
Total weight loss
11.1%
ATTAIN-1 · highest-dose arm · week 72 · Includes treatment stops
Placebo-adjusted
9.0%
Difference from placebo in the same study when reported.
Study context
Oral GLP-1 receptor agonist/Adults with obesity or overweight, without diabetes/3127 participants across the study/72-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
ATTAIN-1 · highest-dose arm · 72 weeks
Adults with obesity or overweight, without diabetes. 3,127 participants across the study (not this dose arm alone).
Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment.
- Average weight loss
- 11.1%
- Placebo group
- 2.1% loss
- Beyond placebo
- 9 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Score: 70% × 44.8 total-loss points + 30% × 45.0 beyond-placebo points = 45/100, rounded. Conversion scales
Alternative analysis assuming continued treatment: 12.4% total loss. This is not the result used for the headline score. Alternative analysis source ↗
Lilly, Foundayo approval ↗Phase 3 · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
ATTAIN-1: Includes treatment stops.
Diabetes data
Orforglipron diabetes trials are clinically relevant but should be interpreted separately from ATTAIN-1 obesity data.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
The approval release describes mostly mild-to-moderate gastrointestinal adverse events, most commonly nausea, constipation, diarrhea, vomiting, dyspepsia, and abdominal pain.
Main cautions
Full label review should guide patient-specific risk discussion; convenience does not remove GLP-1 class tolerability questions.
Upcoming catalyst
What to watch next
Launch uptake and head-to-head positioning against oral semaglutide and injectables.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT05869903
Phase 3
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
Non-diabetic obesity
Nov 5, 2025
NCT06649045
Phase 3
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
Non-diabetic obesity
Sep 29, 2025
NCT06972459
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Eli Lilly and Company
Non-diabetic obesity
Mar 25, 2026
NCT06672549
Phase 3
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company
Non-diabetic obesity
Mar 24, 2026
NCT06948422
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Eli Lilly and Company
Non-diabetic obesity
Mar 24, 2026
NCT07202884
Phase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company
Non-diabetic obesity
Mar 20, 2026
NCT07153471
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Eli Lilly and Company
Non-diabetic obesity
Mar 20, 2026
NCT06952530
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Eli Lilly and Company
Non-diabetic obesity
Mar 20, 2026
NCT06948435
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Eli Lilly and Company
Non-diabetic obesity
Mar 20, 2026
NCT06672939
Phase 3
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Eli Lilly and Company
Non-diabetic obesity
Nov 5, 2025
NCT06584916
Phase 3
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Eli Lilly and Company
Non-diabetic obesity
Dec 22, 2025
NCT05931380
Phase 3
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Eli Lilly and Company
Non-diabetic obesity
Aug 12, 2025